icon-    folder.gif   Conference Reports for NATAP  
 
  20th Conference on Retroviruses and
Opportunistic Infections
Atlanta, GA March 3 - 6, 2013
Back grey_arrow_rt.gif
 
 
 
12 WEEKS OF ABT-450/r, NON-NUCLEOSIDE INHIBITOR AND RBV ACHIEVED SVR24 IN >90% OF TREATMENT-NÁVE HCV GT1 PATIENTS AND 47% OF PRIOR NONRESPONDERS
 
 
  Reported by Jules Levin
20th Conference on Retroviruses and Opportunistic Infections
Atlanta, GA · March 3-6, 2013
 
Eric Lawitz1, Daniel E. Cohen2, Fred Poordad1, Kris V. Kowdley3, Gregory T. Everson4, Bradley Freilich5, Donald Jensen6, Tami Pilot-Matias2, Barry Bernstein2 1: University of Texas Health Science Center, San Antonio, TX, 2: AbbVie Inc., North Chicago, IL, 3: Digestive Disease Institute, Virginia Mason Medical Center, Seattle, WA, 4: University of Colorado Denver and University of Colorado Hospital, Aurora,CO, 5: Kansas City Gastroenterology & Hepatology, Kansas City, MO, 6: Center for Liver Diseases, University of Chicago Medical Center Chicago, Chicago, IL

CROI1.gif

CROI2.gif

CROI3.gif

CROI4.gif

CROI5.gif

CROI6.gif

CROI7.gif

CROI8.gif

CROI9.gif

CROI10.gif

CROI11.gif

CROI12.gif

CROI13.gif